MedTrace Logo

Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors

NCT05689853 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2026-03-18

No results posted yet for this study

Summary

This is a Phase Ib/II study to assess the safety, tolerability and preliminary efficacy of AK119 combined with AK112 in patients with advanced solid tumors.

Conditions

  • Solid Tumor, Adult

Interventions

DRUG

AK119

AK119 is an anti-CD73 monoclonal antibody.

DRUG

AK112

AK112 is a bispecific monoclonal antibody against VEGF and PD-1.

Sponsors & Collaborators

Principal Investigators

  • Wenming Wu, PhD · Peking Union Medical College Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-14
Primary Completion
2026-12-31
Completion
2027-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05689853 on ClinicalTrials.gov